After 50 years, Sanofi is giving itself a bit of a branding make-over with a new logo and a restructuring of the France-based company’s corporate umbrella in support of its three-year-old “Play to Win” strategy.
With two assets licensed from Takeda, Oak Hill Bio launched with a focus on developing therapeutics for patients and extremely preterm infants who are suffering from rare autoimmune diseases.
Kyverna Therapeutics secured an additional $85 million following a successful Series B financing round to support various projects in the company’s pipeline of therapies for autoimmune and inflammatory diseases.
Incyte Corporation withdrew the New Drug Application (NDA) for the company’s candidate drug for various types of lymphoma.
Zymeworks provided a corporate update that included a string of clinical trial news. Additionally, 10 members of Zymeworks’ senior management team are leaving the clinical-stage biopharmaceutical company and the employee headcount will be cut by at least 25 percent by the end of 2022.
Ceptur Therapeutics – based in Hillsborough, NJ, Philadelphia and Copenhagen – closed on a Series A financing round worth $75 million.
Novartis is expanding the company’s position in gene therapy and retinal diseases with the $1.5 billion acquisition of UK-based ocular gene therapy company Gyroscope Therapeutics.
BridgeBio Pharma secured credit assistance worth as much as $750 million to move forward with the company’s research and development efforts for the treatment of cancers and genetic diseases.
Organon announced the women’s health company is acquiring Finland-based Forendo Pharma, which focuses on intracrinology or sex steroid physiology in women.
AstraZeneca said on Nov. 1 the company will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million, as the Anglo-Swedish drugmaker looks to offload its older portfolio of medicines.
